Tumor initiating cells (TICs) differ from normal stem cells (SCs) in their ability to initiate tumorigenesis, invasive growth, metastasis and the acquisition of chemo and/or radio-resistance. In the last years, several studies have indicated the potential role of the Notch system as a key regulator of cellular stemness and tumor development.
This basal cell compartment constitutes the internal repair and self-renewal system in normal tissues. It is this balance between cellular self-renewal and differentiation what maintains normal tissue architecture and function. Therefore, it is not surprising that molecular derangements that affect this highly regulated process can lead to uncontrolled cellular growth, aberrant differentiation and tumor development.
The proposed existence of a population of tumor initiating cells (TIC) that mediate tumorigenesis and cancer progression has forced us to revisit our understanding of the fundamental processes governing cancer development. Unlike normal SCs, TICs have lost their stringent regulation and display a tendency for tumorigenesis, cellular invasiveness and metastatic potential [1] . The renewed interest in the study of TIC biology stems from the fact that their identification and therapeutic targeting may result, not only on improved tumor responses, but also in the potential eradication of neoplastic cells associated with pharmacologic resistance and disease relapse.
Several hypotheses have been proposed to account for the origin and development of TICs. The stochastic model suggests that normally differentiated cells can acquire a transformed phenotype capable of driving tumorigenesis through clonal evolution.
Alternatively, the hierarchic model proposes that normal SCs may undergo an oncogenic event and subsequently serve as a continuous source of neoplastic cells, intrinsically resistant to standard therapeutic interventions. These two views are not necessarily mutually exclusive and a combined model may account for tumor development and progression, more accurately [2] . For example, TICs may originate either from normal SCs or more differentiated progenitors that acquire the capacity for self-renewal, invasive TICs" (mTICs) which possess both stemness and migratory capabilities associated with the acquisition of epithelial-mesenchymal transition (EMT) phenotype [3] . This switch from
SCs to mTICs appears to relate, not only to genetic alterations, but also to microenvironmental factors. These permissive micro-environmental niches may promote TIC proliferation and differentiation into invasive and metastatic cell populations, resulting in tumor progression and the emergence of resistance to standard treatments.
TICs are usually characterized by the expression and/or deregulation of genes involved in embryonic development, such as the Hedgehog, Notch and Wnt signaling pathways. These three signaling pathways appear to be fundamental in TIC biology and represent promising targets for therapeutic intervention [4] . In the next sections we will discuss the role of the Notch signaling pathway in cellular stemness and tumorigenesis, as well as its interaction with the family of proteins known as cancer testis antigens (CTAs), recently found to be expressed on TICs [5] .
The Notch pathway
The Notch family of proteins includes a total of four highly homologous receptors (Notch-1, Notch-2, Notch-3, Notch-4) with important roles in the regulation of various processes, including neurogenesis, gliogenesis, myogenesis, vasculogenesis, hematopoiesis and epidermal development [6] . The Notch system is involved in the homeostasis of adult tissues by promoting self-renewal of SCs, determining cell fate (such as commitment towards T or B cell lineage) and regulating the differentiation of many cell types. Because of its extensive involvement in all these processes, mutations and/or deregulation of Notch receptors and/or ligands has been associated with the genesis of various malignancies [7] . Notch signaling depends on its interaction with specific ligands, proteolytic cleavage, release of Notch's cytoplasmic portion and subsequent translocation to the nucleus [8] . In vertebrates, two closely related families of ligands are capable of interacting with Notch receptors: the Delta-like (DLL-1, -3, -4 and DLL-2, described only in Xenopus) and the Serrate-like (Jagged1 and 2) ligands [9] . Notch signaling is dependent on cell-to-cell communication and is activated when Notch ligands, present on the "sending cell", bind to Notch receptor on the "receiving cell". MyoD in myogenesis and E2A in B lymphopoiesis), the pre-TCR alpha (which participates in regulating the T cell progenitors differentiation), cell cycle regulatory genes such as cyclin D2, cyclin D1, p21 and p27, and genes from different chemokine systems [11, 12, 13] .
Notch signaling is involved in the regulation of SC fate, in both embryonic and adult tissues. Activation of the Notch pathway has been shown to regulate the transit of nervous
SCs from quiescence to a proliferative state and, together with Wnt signaling, also coordinates proliferation and differentiation of intestinal SCs [14] . Since deregulation of the Notch system has been shown to be involved in the patho-biology of many neoplasms, it is not surprising this signaling pathway is of fundamental importance in the molecular processes involved in TIC development.
Notch and TICs
Activation of the Notch system promotes self-renewal of TICs in several malignancies and participates in the interactions between tumor cells and the microenvironment, in both primary and metastatic neoplasms [15] . The Notch signaling pathway regulates not only the formation of TICs, but also their acquisition of the EMT phenotype which promotes metastasis and drug resistance [16] . Notch signaling has been demonstrated to be crucial in neural SCs biology based on its ability to inhibit neuronal differentiation [17] . The observation that Notch activation up-regulates AKT and MCL-1 expression in glioma SCs after radiation, indicates its importance in mediating resistance [19] . Notch and Wnt pathways also play crucial roles in coordinating proliferation and differentiation of intestinal stem cells in mice [14] , and their activation leads to amplification of the intestinal SC/progenitor cell pool and inhibition of cell differentiation [20] . The importance of Notch signaling in gastrointestinal tissues is further supported buy its association with chemotherapy resistance in gastric tumors [21] and up-regulation of Notch1 and HES1 in colon adenocarcinomas, compared to normally differentiated colonic cells [22] . Since maintenance of undifferentiated, proliferative cells in intestinal crypts and adenomas requires activation of the Notch pathway, inhibition of Notch signaling by γ-secretase inhibitors has been proposed as a treatment for colorectal cancer [23] .
The Notch pathway is also deregulated in breast cancer (BC) and its activation may protect BCs from drug-induced apoptosis [24, 25] . Indeed, Notch signaling has been suggested as one of the conserved developmental pathways leading to TIC maintenance and resistance to conventional chemotherapy in this disease [26] . In ovarian cancer (OC)
Notch3 activation has been associated with chemo-resistance and poor prognosis [27, 28] .
McAuliffe et al. have demonstrated over-expression of Notch3 in OC is associated with an increased TIC population and development of resistance to cisplatin, while Notch3 inhibition results in reduction of TICs and restoration of sensitivity to platinum agents [29] .
Aberrations in Notch signaling have also been linked to several hematological malignancies, including T-cell acute lymphoblastic leukemia (T-ALL), acute myeloid leukemia (AML), lymphoma and multiple myeloma (MM) [6, 12] . The role of Notch signaling in hematopoiesis and in hematopoietic SC (HSC) development and maintenance has been extensively reviewed by Bigas and Espinosa [30] , the fundamental finding being that activation of the Notch pathway is necessary for HSCs maintenance, and its inhibition results in HSCs differentiation and depletion [31] . The role of Notch signaling in the biology of leukemic SCs (LSCs), however, appears to be context-dependent and requires further study before its importance is completely understood in these diseases [31] . [53] . In this study, SP17-loaded autologous dendritic cells (DCs) were used to treat a MM patient, who had developed disease progression, and resulted in SP17-specific immunity and reduction of serum paraprotein levels [53] . Based on these preliminary results, evaluation of this CTA sub-group of scaffolding sperm proteins is clearly warranted in a larger group of MM patients. More importantly, further studies to unravel the link between CTA expression and TIC biology are necessary in order to develop effective TIC-targeted therapies in the future. Since the process of malignant transformation may be defined by mutational deregulation of SC programs for self-renewal and differentiation, CTA expression may serve, not only as a potential marker of tumor cell stemness, but as an attractive target for treatment of TIC-dependent metastatic, recurrent and/or resistant disease [57] .
Cancer Testis Antigens
Expression of CTAs in tumor SCs or TICs has been evaluated in several tumor models. GBM is a primary glial malignancy believed to have a defined SC population [58] .
CD133 expression has been suggested as a marker of stemness in this malignancy based on the observation that CD133 positive cells can give rise to tumorigenic cells [58, 59] .
Interestingly, CTAs such as LAGE-1, NY-ESO-1 and MAGE family members are also expressed in GBM CD133 positive cells, compared with differentiated or parent cells [59] .
Moreover, the expression of MAGE family members and CD133 is down-regulated as cells become more differentiated, indicating a correlation between expression of these molecules and the undifferentiated cellular state [59] . Since CD133 negative GBM cells can also be tumorigenic [58] , CD133 expression can't be considered a specific marker for GBM stemness. Therefore, determination of expression of certain CTA expression patterns could be helpful in determining cellular stemness among CD133 negative GBM 
Interactions between Notch signaling and CTA expression in TICs: Lessons from MM.
The discovery of embryonic, germinal and tumor-restricted expression of CTAs has advanced the hypothesis of a functional correlation between embryogenesis, gametogenesis, and tumorigenesis [61, 62] . These observations have partially resurrected John Beard's "Trophoblastic Theory of Cancer" proposing that all tumors carry a population of cells with germ-like features originating from germinal cells which have failed to migrate to the gonads [63] . Thus, aberrant CTA expression in tumors may reflect reactivation of a gametogenic program involved in maintenance of stemness in specific cellular compartments, such as TICs [62] . As previously discussed, there is evidence supporting the hypothesis that the Notch pathway may also be associated with reactivation of a germinal cell transcription program in TICs. Since Notch signaling is an important regulator of germ cell development, it is likely that the common expression pattern shared by Notch1 and CTAs in germ cells [14] [15] [16] [17] [18] reflects a biologically relevant interaction between these two pathways.
Several CTAs are expressed in MM cells and their expression appears to play an important role in cell proliferation and resistance to apoptosis [60, [64] [65] [66] [67] . Our group was the first to identify expression of two novel CTAs, AKAP-4 and SP17, in more than 75% of MM cell lines and patients [37] . Jungbluth et al. have reported expression of MAGE-C1
and MAGE-A3/6 in MM, their expression correlating with MM cell proliferation [68] . CTA [69] . CTA expression in malignant MM cells has also been correlated with the activation of Notch signaling through the Jagged-2 ligand [70] .
Moreover, activation of Notch signaling has been associated with drug resistance, as well as cross-talk between MM cells and bone marrow microenvironment [71, 72] , the latter being a critical requirement for maintenance of MM SC population [67] .
In vitro and in vivo studies support a "compartmental model" for MM. In this model two cellular compartments exist: 1. a small, proliferating fraction of self-renewing progenitor cells (the so called MM SC); 2. a non-proliferating compartment exhibiting plasma cell differentiation and resistance to apoptosis [73] . Here, we propose a different model in which Notch signaling and CTA expression interact to maintain a self-replicating MM cell population. Although CTA expression has been described in a broad range of solid and hematologic malignancies [33, 35, 36, 39, 40, 41, 43] , MM is distinct in that a significant majority of patients express AKAP-4 and/or SP17 in their tumor cells [34, 37, 38, 42] . No other type of cancer has such a close association with specific CTA expression pattern. To date, the molecular and biological actions of SP17 and AKAP4 are incompletely understood. Nonetheless, several reports have implicated SP17 in cell-to-cell adhesion and/or cell migration of lympho-hematopoeitic cells, possibly through its heparan sulphate binding domain [74] . SP17 has two additional functional domains, an N-terminal domain highly conserved among mammals and 45% identical to the type II alpha regulatory subunit of protein kinase A (RII-PKA) and a C-terminal calmodulin binding domain [75, 76] . AKAPs represent a family of proteins characterized by their ability to bind and regulate PKA function by localizing this critical enzyme to specific sub-cellular 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 60 It is evident that any strategy designed to increase expression of cancer-restricted antigens would result in better responses to cancer vaccine strategies [86] . Regulation of CTA expression in tumors of different histological origin is based on epigenetic tuning of promoter availability and chromatin remodeling [87] [88] [89] [90] . Notch signaling has been shown to down-regulate the expression of specific targets by increasing promoter methylation in genes such as pRb and vascular endothelial growth factor receptor (VEGFR)-2 [91] .
Therefore, the possibility exists that Notch signaling may contribute to mitigate the expression of CTAs in selected tumoral sub-populations, such as TICs. In this scenario, Notch-inhibiting agents, in combination with CTA-targeting vaccines, would improve therapeutic efficacy by increasing the probability of TIC eradication. Additionally, inhibition of Notch signaling by itself is expected to reduce the self-renewal ability of TICs, which would then make these cells more susceptible to CTA-specific cytotoxic lymphocyte killing.
The potential drawback of this approach, however, would be the lack of tumor specificity of Notch targeting, compared with CTA targeting. Currently, the only strategy tested in patients to inhibit Notch signaling is the use γ-secretase inhibitors, which results in serious gastrointestinal toxicity due to induction of intestinal metaplasia, a consequence of deregulation of goblet cell differentiation in the intestine [92, 93] . Intestinal metaplasia is caused by the concurrent inhibition of both Notch1 and 2, indicating independent targeting of Notch1 or Notch2 specific antibodies may eliminate the observed toxicity, as demonstrated animal models of acute leukemias [94] . The use of antibodies that specifically block tumor-associated Notch isoforms, and/or their ligands, represent a potential alternative to toxic demethylating agents, such as 5-aza-2'-deoxycytidine, and γ-secretase inhibitors [95] . As discussed above, selective Notch blockade would result in increased CTA expression by TICs making these more susceptible to the cytotoxic effects of therapeutic cancer vaccines. To date, several clinical trials are evaluating the safety and efficacy of Notch inhibition in both solid and hematological malignancies, including MM (www.clinicaltrials.gov). These studies should provide the necessary information to design future clinical trials combining Notch inhibition and CTA overexpression and immunotargeting for the treatment of selective cancers [86, 95, 96] . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42 
